These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34904813)

  • 1. DNA Damage Repair Inhibitors-Combination Therapies.
    Smith G; Alholm Z; Coleman RL; Monk BJ
    Cancer J; 2021 Nov-Dec 01; 27(6):501-505. PubMed ID: 34904813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Damage Response in Prostate and Breast Cancer.
    Wengner AM; Scholz A; Haendler B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage response pathways in tumor suppression and cancer treatment.
    Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
    World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to DNA repair inhibitors in cancer.
    Baxter JS; Zatreanu D; Pettitt SJ; Lord CJ
    Mol Oncol; 2022 Nov; 16(21):3811-3827. PubMed ID: 35567571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
    Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
    Yang SH; Kuo TC; Wu H; Guo JC; Hsu C; Hsu CH; Tien YW; Yeh KH; Cheng AL; Kuo SH
    World J Gastroenterol; 2016 Aug; 22(32):7275-88. PubMed ID: 27621574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
    Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
    Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State-of-the-art strategies for targeting the DNA damage response in cancer.
    Pilié PG; Tang C; Mills GB; Yap TA
    Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.
    Chou WC; Hu LY; Hsiung CN; Shen CY
    Carcinogenesis; 2015 Aug; 36(8):832-40. PubMed ID: 26025911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the DNA damage response for cancer therapy.
    Curtin NJ
    Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Targeting of DNA Damage Response in Cancer.
    Choi W; Lee ES
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
    Mao X; Lee NK; Saad SE; Fong IL
    Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
    Genta S; Martorana F; Stathis A; Colombo I
    Crit Rev Oncol Hematol; 2021 Dec; 168():103539. PubMed ID: 34800653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directing the use of DDR kinase inhibitors in cancer treatment.
    Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage repair in breast cancer and its therapeutic implications.
    Ali R; Rakha EA; Madhusudan S; Bryant HE
    Pathology; 2017 Feb; 49(2):156-165. PubMed ID: 28034453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
    Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
    [No Abstract]   [Full Text] [Related]  

  • 20. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.